Nordic Life Science 1
WuXi AppTec ADVERTORIAL Navigating the drug devel
opment journey with WuXi AppTec IN TODAY'S RACE to bring new medicines to patients, WuXi AppTec has positioned itself as a key partner in helping companies translate scientific discoveries into innovative therapies. W UXI APPTEC is a leading global CRDMO, providing comprehensive pharmaceutical services across Europe, Asia, and North America. Since its establishment in 2000, the company has supported thousands of partners in more than 30 countries, helping to advance scientific discoveries into transformative therapies. Its end-to-end capabilities cover every stage of drug development – from early-stage research and preclinical studies to large-scale manufacturing – designed to accelerate the delivery of effective treatments to patients worldwide. WuXi AppTec has a solid presence in Europe, with dedicated facilities in Germany and Switzerland. The company also has a strong foothold in Scandinavia, where it currently collaborates with I N T E R V I E W W I T H DR. THOMAS ME I NS , GENER AL MANAGER AND S I TE HEAD OF CR ELUX , A WUXI APPTEC COMPANY around 60 organizations engaged in preclinical drug discovery. Its German subsidiary Crelux runs WuXi AppTec’s brand new state-of-the-art facility in Munich – the company moved into the new premises with customized spatial and technical infrastructure only last year. Dr. Thomas Meins is the site head and general manager of Crelux. Speaking to the advantages of partnering with WuXi AppTec, Thomas Meins explains the many benefits of working PHOTO CRELUX, A WUXI APPTEC COMPANY